80.2 USD
-0.31 (-0.39%)
We assign a fundamental rating of 4 out of 10 to MLAB. MLAB was compared to 58 industry peers in the Life Sciences Tools & Services industry. MLAB has a medium profitability rating, but doesn't score so well on its financial health evaluation. MLAB has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
MLAB had negative earnings in the past year.
In the past year MLAB had a positive cash flow from operations.
In multiple years MLAB reported negative net income over the last 5 years.
Each year in the past 5 years MLAB had a positive operating cash flow.
1.2 Ratios
MLAB's Return On Assets of -0.37% is fine compared to the rest of the industry. MLAB outperforms 67.24% of its industry peers.
MLAB has a Return On Equity of -0.88%. This is in the better half of the industry: MLAB outperforms 68.97% of its industry peers.
With a decent Return On Invested Capital value of 3.11%, MLAB is doing good in the industry, outperforming 65.52% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for MLAB is significantly below the industry average of 13.53%.
The 3 year average ROIC (1.90%) for MLAB is below the current ROIC(3.11%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROIC | 3.11% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
1.3 Margins
Looking at the Operating Margin, with a value of 6.13%, MLAB is in the better half of the industry, outperforming 60.34% of the companies in the same industry.
In the last couple of years the Operating Margin of MLAB has remained more or less at the same level.
With an excellent Gross Margin value of 62.15%, MLAB belongs to the best of the industry, outperforming 82.76% of the companies in the same industry.
MLAB's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% |
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
2. Health
2.1 Basic Checks
MLAB has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for MLAB has been increased compared to 1 year ago.
Compared to 5 years ago, MLAB has more shares outstanding
Compared to 1 year ago, MLAB has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.28, we must say that MLAB is in the distress zone and has some risk of bankruptcy.
MLAB has a worse Altman-Z score (1.28) than 62.07% of its industry peers.
MLAB has a debt to FCF ratio of 4.69. This is a neutral value as MLAB would need 4.69 years to pay back of all of its debts.
The Debt to FCF ratio of MLAB (4.69) is better than 70.69% of its industry peers.
A Debt/Equity ratio of 0.95 indicates that MLAB is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.95, MLAB is doing worse than 77.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Altman-Z | 1.28 |
ROIC/WACC0.32
WACC9.8%
2.3 Liquidity
A Current Ratio of 2.02 indicates that MLAB has no problem at all paying its short term obligations.
The Current ratio of MLAB (2.02) is worse than 60.34% of its industry peers.
MLAB has a Quick Ratio of 1.44. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.44, MLAB is not doing good in the industry: 62.07% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
MLAB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -104.68%.
The earnings per share for MLAB have been decreasing by -39.16% on average. This is quite bad
The Revenue has been growing slightly by 7.39% in the past year.
MLAB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.41% yearly.
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
3.2 Future
MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 231.94% yearly.
The Revenue is expected to grow by 4.64% on average over the next years.
EPS Next Y2471.86%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.64%
Revenue Next 5YN/A
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
MLAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 51.90, the valuation of MLAB can be described as expensive.
MLAB's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of MLAB to the average of the S&P500 Index (36.59), we can say MLAB is valued slightly more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 51.9 |
4.2 Price Multiples
MLAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. MLAB is cheaper than 89.66% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MLAB is valued cheaply inside the industry as 98.28% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.87 | ||
| EV/EBITDA | 14.99 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MLAB may justify a higher PE ratio.
A more expensive valuation may be justified as MLAB's earnings are expected to grow with 231.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y369.85%
EPS Next 3Y231.94%
5. Dividend
5.1 Amount
MLAB has a yearly dividend return of 0.79%, which is pretty low.
Compared to an average industry Dividend Yield of 0.47, MLAB pays a better dividend. On top of this MLAB pays more dividend than 100.00% of the companies listed in the same industry.
With a Dividend Yield of 0.79, MLAB pays less dividend than the S&P500 average, which is at 2.34.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
5.2 History
The dividend of MLAB decreases each year by -0.50%.
MLAB has paid a dividend for at least 10 years, which is a reliable track record.
MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years21
5.3 Sustainability
The earnings of MLAB are negative and hence is the payout ratio. MLAB will probably not be able to sustain this dividend level.
DP-222.26%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
NASDAQ:MLAB (11/28/2025, 7:48:23 PM)
80.2
-0.31 (-0.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners96.24%
Inst Owner Change-11.9%
Ins Owners5.28%
Ins Owner Change6.18%
Market Cap442.70M
Revenue(TTM)245.25M
Net Income(TTM)-1.57M
Analysts80
Price Target96.9 (20.82%)
Short Float %7%
Short Ratio2.54
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.79% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP-222.26%
Div Incr Years0
Div Non Decr Years21
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)133.29%
Min EPS beat(2)90.84%
Max EPS beat(2)175.74%
EPS beat(4)2
Avg EPS beat(4)-16.43%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)416.54%
EPS beat(12)5
Avg EPS beat(12)215.06%
EPS beat(16)7
Avg EPS beat(16)156.44%
Revenue beat(2)0
Avg Revenue beat(2)-2.79%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-1.95%
Revenue beat(4)1
Avg Revenue beat(4)-0.43%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)4.83%
Revenue beat(8)3
Avg Revenue beat(8)-0.19%
Revenue beat(12)3
Avg Revenue beat(12)-1.93%
Revenue beat(16)6
Avg Revenue beat(16)0.23%
PT rev (1m)7.34%
PT rev (3m)7.34%
EPS NQ rev (1m)-13.48%
EPS NQ rev (3m)-43.8%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.77%
Revenue NQ rev (1m)-1.46%
Revenue NQ rev (3m)-1.46%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 51.9 | ||
| P/S | 1.81 | ||
| P/FCF | 11.87 | ||
| P/OCF | 10.74 | ||
| P/B | 2.48 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.99 |
EPS(TTM)-0.27
EYN/A
EPS(NY)1.55
Fwd EY1.93%
FCF(TTM)6.76
FCFY8.43%
OCF(TTM)7.47
OCFY9.31%
SpS44.43
BVpS32.33
TBVpS-18.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.37% | ||
| ROE | -0.88% | ||
| ROCE | 3.94% | ||
| ROIC | 3.11% | ||
| ROICexc | 3.28% | ||
| ROICexgc | 14.87% | ||
| OM | 6.13% | ||
| PM (TTM) | N/A | ||
| GM | 62.15% | ||
| FCFM | 15.21% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)1.9%
ROIC(5y)1.6%
ROICexc(3y)2.1%
ROICexc(5y)2.03%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.4%
ROCE(5y)2.02%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y106.13%
ROICexc growth 5Y21.15%
OM growth 3Y38.53%
OM growth 5Y0.45%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.88%
GM growth 5Y2.57%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.95 | ||
| Debt/FCF | 4.69 | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 15.81% | ||
| Cap/Sales | 1.6% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 103.47% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.02 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.28 |
F-Score5
WACC9.8%
ROIC/WACC0.32
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-104.68%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%-43.61%
EPS Next Y2471.86%
EPS Next 2Y369.85%
EPS Next 3Y231.94%
EPS Next 5YN/A
Revenue 1Y (TTM)7.39%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%5.02%
Revenue Next Year3.51%
Revenue Next 2Y4.37%
Revenue Next 3Y4.64%
Revenue Next 5YN/A
EBIT growth 1Y22.54%
EBIT growth 3Y51.48%
EBIT growth 5Y15.93%
EBIT Next Year171.2%
EBIT Next 3Y46.94%
EBIT Next 5YN/A
FCF growth 1Y2.55%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y3.18%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 4 / 10 to MLAB.
Can you provide the valuation status for MESA LABORATORIES INC?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
How profitable is MESA LABORATORIES INC (MLAB) stock?
MESA LABORATORIES INC (MLAB) has a profitability rating of 6 / 10.
Is the dividend of MESA LABORATORIES INC sustainable?
The dividend rating of MESA LABORATORIES INC (MLAB) is 4 / 10 and the dividend payout ratio is -222.26%.